Table 4
Densitmetric evaluation of NF-κBp65 signals obtained on western blot analysis of resection specimens from patients with Crohn’s disease treated with and without glucocorticoids
| Patient | Cytoplasmic NF-κBp65 (arbitrary units) | Nuclear NF-κBp65 (arbitrary units) | NF-κBp65 activity coefficient |
|---|---|---|---|
| Without glucocorticoids | |||
| 1 | 5.825 | 10.603 | 1.821 |
| 2 | 7.117 | 14.637 | 2.056 |
| 5 | 5.805 | 9.561 | 1.866 |
| 6 | 9.328 | 11.911 | 1.277 |
| 7 | 5.437 | 5.337 | 0.981 |
| 8 | 14.73 | 8.7 | 0.591 |
| 10 | 2.855 | 2.896 | 1.014 |
| 11 | 5.948 | 5.879 | 0.983 |
| 13 | 7.252 | 7.58 | 1.045 |
| 14 | 10.941 | 23.08 | 2.109 |
| With glucocorticoids | |||
| 3 | 10.618 | 5.919 | 0.557 |
| 4 | 3.899 | 1.788 | 0.459 |
| 9 | 16.656 | 6.473 | 0.388 |
| 12 | 3.347 | 1.757 | 0.524 |
| 15 | 6.463 | 3.606 | 0.557 |
-
The determination of the signal area to be measured and the quantitative evaluation was performed twice in two independent experiments. The mean of the two measurements is given. To adjust for individual differences in NF-κB expression, the ratio of nuclear NF-κBp65 to cytoplasmic NF-κBp65 was calculated to establish an NF-κBp65 activity coefficient.
